Acrux Limited · ASX:ACR
Acrux — Bioshares Thredbo Biotech Summit 2009
9 slides from Acrux's conference presentation, Sep 1, 2009
Slide 1: Bioshares Thredbo Biotech Summit
For personal use only Bioshares Thredbo Biotech Summit 28 August 2009
Slide 2: Evolution of Testosterone Therapy
Evolution of Testosterone Therapy For personal use only • Short acting testosterone injections 1950’s • Roller coaster effect, supraphysiological levels • Painful injection, frequent doctor visits • Capsules (Andriol®) 1970’s • Poor and variable T levels obtained, 4 to 6 caps daily • Long term use c
Slide 3: Testosterone Market Size
Testosterone Market Size For personal use only INJ/OTHER ANDRODERM TESTIM ANDROGEL $900,000 $800,000 $62,671 LATIN AMERICA, $32,468 , 3% $60,571 $700,000 ASIA/AFRICA/AUS, $59,333 $141,389 $600,000 Sales USD 000's $53,118 , 5% $55,601 $56,575 $500,000 $104,792 NORTH AMERICA, $55,310 EUROPE , $850,662
Slide 4: Prevalence of Low Testosterone
Prevalence of Low Testosterone 60,000,000 60% For personal use only 54,568,075 50% 50,000,000 50% 46% 40% 40% 40,000,000 39% 40% 34% % of Men with Low T** Male Population* 30,000,000 30% 20,000,000 20% 10,000,000 10% 0 0% Total 45+ 45 to 54 55-64 65-74 75-84 85+ US Male Population Age Groups *Popula
Slide 5: About AXIRON
About AXIRON™ • AXIRON™ is a transdermally applied, testosterone For personal use only replacment therapy for men – Substitutive Treatment of Testosterone Deficiency confirmed by biological and clinical signs in hypogonadal men. • Unique application site ensures product will provide clear differenti
Slide 6: Maximising the value of AXIRON
Maximising the value of AXIRON™ Understand the market drivers and competitive landscape For personal use only Determine the unmet needs and establish a clear target product profile Strengthen patent protection of key attributes Validate benefits with patients and prescribers in the target market Det
Slide 7: Competitive Product Position
Competitive Product Position For personal use only Drying time Site of Container Amount Area of Product How applied (in-vitro application Type Dosed dosing test) Metered No touch AXIRON™ Axilla only 3.0mL < 600cm2 <3 mins Dose Pump applicator Individual abdomen, or sachets or Approx 600- Androgel® s
Slide 8: Positive Acceptance by Patients
Positive Acceptance by Patients Product test of 63 participants, Asked to directly For personal use only AXIRON™ placebo all existing users compare AXIRON™ at home for 4 of Androgel and with their days Testim existing gel Much Worse/Worse Somewhat Better/Better/Much Better Time to Clean Up -9% -26%
Slide 9: Positive acceptance by Physicians
Positive acceptance by Physicians For personal use only 90.8% of all physicians rated AXIRON™ as very good or excellent in being able to improve the patient experience when compared to existing gel treatments. 92.4% of physicians who prescribe gel as their First Line Therapy rated AXIRON™ as very go